Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1650 of 2873 entries
View as:

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02706353 Org: User:
Start: 06/02/17 End: 04/30/25 Due: 04/30/26

Functional Outcomes Following Limb Sparing Surgery for Sarcoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT00508339 Org: User:
Start: 09/30/06 End: 10/31/07 Due: 10/31/08

Cancer Patients Diagnosed With Unsuspected Venous Thromboembolism (VTE) on Routine Computed Tomography (CT) Scans

Phase: N/A Priority: Normal
NCT ID: NCT00925808 Org: User:
Start: 06/30/09 End: 06/30/21 Due: 06/30/22

Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00496587 Org: User:
Start: 07/31/07 End: 05/31/16 Due: 05/31/17

Docetaxel and Sirolimus in Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01054313 Org: User:
Start: 01/31/10 End: 10/31/14 Due: 10/31/15

Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00061620 Org: User:
Start: 09/06/01 End: 02/12/04 Due: 02/12/05

Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT00523809 Org: User:
Start: 08/31/07 End: 10/31/11 Due: 10/31/12

Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

Phase: N/A Priority: Normal
NCT ID: NCT03121534 Org: User:
Start: 06/22/17 End: 02/11/22 Due: 02/11/23

Colorectal Cancer Umbrella Protocol - Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC Program) Screening Protocol

Phase: N/A Priority: Normal
NCT ID: NCT01196130 Org: User:
Start: 08/31/10 End: 12/09/22 Due: 12/09/23

Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03432676 Org: User:
Start: 07/31/19 End: 04/30/21 Due: 04/30/22

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00494182 Org: User:
Start: 04/25/07 End: 12/31/25 Due: 12/31/26

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT03066206 Org: User:
Start: 03/17/17 End: 12/31/25 Due: 12/31/26

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT04160052 Org: User:
Start: 10/01/19 End: 12/31/25 Due: 12/31/26

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT06548230 Org: User:
Start: 01/01/25 End: 12/01/29 Due: 12/01/30

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00877500 Org: User:
Start: 03/30/09 End: 12/31/26 Due: 12/31/27

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT04038619 Org: User:
Start: 02/01/21 End: 12/31/25 Due: 12/31/26

Impact Of Muscle Vibration On Gait Control

Phase: N/A Priority: Normal
NCT ID: NCT05061238 Org: User:
Start: 10/04/21 End: 12/31/25 Due: 12/31/26

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03581487 Org: User:
Start: 04/01/19 End: 12/31/25 Due: 12/31/26

Magnetic Resonance Imaging of Gynecologic Malignancies Involving the Vagina

Phase: N/A Priority: Normal
NCT ID: NCT01703195 Org: User:
Start: 11/30/12 End: 09/19/19 Due: 09/19/20

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

Phase: N/A Priority: Normal
NCT ID: NCT05195710 Org: User:
Start: 11/16/22 End: 03/31/26 Due: 03/31/27

Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection

Phase: N/A Priority: Normal
NCT ID: NCT02210078 Org: User:
Start: 02/19/15 End: 08/31/25 Due: 08/31/26

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02210117 Org: User:
Start: 11/25/14 End: 11/30/25 Due: 11/30/26

Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01628029 Org: User:
Start: 01/15/14 End: 12/31/25 Due: 12/31/26

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT04745910 Org: User:
Start: 04/05/22 End: 12/31/25 Due: 12/31/26

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Phase: N/A Priority: Normal
NCT ID: NCT02726997 Org: User:
Start: 07/06/16 End: 12/31/25 Due: 12/31/26